Introducing NICE Advice

This week, the National Institute for Health, and Care Excellence (NICE) has launched its refreshed support service for the life sciences sector, NICE Advice. The service will provide accurate and reliable scientific and strategic advice, education, and NHS insights to pharmaceutical and Healthtech companies. It aims to help companies succeed, so that more patients gain access to the best treatments and care. 

NICE Advice offers life science companies the same valued scientific advice and health system engagement meetings provided by NICE’s previous support services, NICE Scientific Advice, and the Office for Market Access.

However, it is now much easier to access, through one single service and a refreshed website. It offers greater flexibility to everyone using it. Healthtech companies will also benefit from a more tailored support offer, that is more closely aligned to their pace of development and budget. 

As England’s health technology assessment body and the only national body to appraise individual medicines or devices, NICE possesses a unique position. It provides trusted, unrivalled expertise in health technology assessment and holds unique NHS insight and experience. Through NICE Advice, this is drawn upon to support life science companies to effectively demonstrate the value of their product. Thereby helping to drive innovation into the hands of health and care professionals.

NICE Advice offers 3 types of support, which can be tailored to the needs and budget of individual companies, whatever your stage of development:

  • Advice - Identifying gaps in evidence, providing actionable technical scientific advice on clinical and economic evidence plans, and quality-checking economic models.
  • Insight – facilitating access to valuable insight, ranging from a 1-hour session with a NICE expert to a 2-3-hour health system engagement meeting with a range of experts. Insight gained can help identify a suitable path to market or address complex market access challenges.
  • Education – A range of free webinars and paid seminars, delivered online or in-person. These cover a broad range of topics relating to NICE’s work including evidence generation, health economic modelling, NICE evaluations and other topics in the world of health technology assessment and evidence-based healthcare. 

These services are confidential and are provided independently of NICE's guidance producing programmes to ensure there are no conflicts of interest.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said: “NICE Advice provides a single point of contact for individuals and organisations across the life sciences sector. By coming to us, they’ll gain access to accurate, reliable and actionable advice, NHS insights and education they can trust. We want to help companies succeed, so that more patients gain access to the best treatments and care.” 

Jeanette Kusel, director of NICE Advice, said: “NICE Advice can help companies prepare for a technology appraisal, or engagement with payers or commissioners. Engaging with us can help save time and money and get innovations into the hands of health and care professionals faster. If you’re unsure about working with NICE, I’d encourage you to come and talk to us.”

To find out more you can submit an enquiry online or visit the NICE Advice website.


More news and updates 

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

Coulter Partners top hires for VC & PE portfolio companies Q1-2024

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

Abzena announces major investment in bioconjugation and ADC capabilities in response to increasing industry demand

Abzena announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.

New £6.2 million partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya

A new £6.2 million healthcare project has begun in Kenya to advance elimination of visceral leishmaniasis, a deadly parasitic disease found in Africa, the Americas, the Middle East and South-East Asia, which affects up to 90,000 children and vulnerable people globally.

New study explores how Switzerland can maintain its leading position in life science innovation

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity Reports: “Sustaining a winning position”, an analysis of how Switzerland can continue to lead the life sciences sector in a shifting global market.

Data from Brainomix’s collaboration with AstraZeneca shows e-Lung better identifies lung fibrosis patients at risk of decline

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.

Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

PrecisionLife and NATA announce R&D partnership to jointly develop new motor neurone disease

Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS. The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development.

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.


More within